Amidation of β-amyloid peptide strongly reduced the amyloidogenic activity without alteration of the neurotoxicity

Journal of Neurochemistry

Volumn 69, Issue 5, 1997, Pages 2048-2054

  Forloni, Gianluigi ^a   Lucca, Elisa ^a   Angeretti, Nadia ^a   Della Torre, Paola ^a   Salmona, Mario ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Amidation; Apoptosis; Hippocampal cultures; Thioflavine S; Amyloid peptide

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; AMIDATION; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN ATROPHY; CELL VIABILITY; CONTROLLED STUDY; FETUS; HIPPOCAMPUS; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; SENILE PLAQUE;

ANIMALIA;

EID: 0030779130     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.69052048.x     Document Type: Article

References (43)

1. 2+ -dependent late phase. J. Neurochem. 67, 2074-2078.
2. Abraham C. A., Selkoe D. J., and Potter H. (1988) Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52, 487-501.
3. Aksenov M. Y., Aksenova M. V., Butterfield D. A., Hensley K., Vigo-Pelfrey C., and Carney J. M. (1996a) Glutamine synthetase-induced enhancement of β-amyloid peptide Aβ(1-40) neurotoxicity accompanied by abrogation of fibril formation and Aβ fragmentation. J. Neureichem. 66, 2050-2056.
4. Aksenov M. Y., Aksenova M. V., Carney J. M., and Butterfield D. A. (1996b) α1-Antichymotrypsin interaction with Aβ(1-42) does not inhibit fibril formation but attenuates the peptide toxicity. Neurosci. Lett. 217, 117-120.
5. Aksenova M., Aksenov M., Butterfield D., and Carney J. (1996) α1-Antichymotrypsin interaction with Aβ(1-40) inhibits fibril formation but does not affect the peptide toxicity. Neurosci. Lett. 211, 45-48.
6. Andreoni G., Angeretti N., Lucca E., and Forloni G. (1997) Densitometric quantification of neuronal viability by computerized image analysis. Exp. Neurol. (in press).
7. Busciglio J., Lorenzo A., and Yankner B. A (1992) Methodological variables in the assessment of beta amyloid neurotoxicity. Neurobiol. Aging 13, 609-612.
8. Buttke T. M. and Sandstrom P.A. (1994) Oxidative stress as a mediator of apoptosis. Immunol. Today 15, 7-10.
9. Cafe C., Torri C., Bertorelli L., Angeretti N., Lucca E., Forloni G., and Marzatico F. (1996) Oxidative stress after acute and chronic application of β amyloid fragment 25-35 in cortical cultures. Neurosci. Lett. 203, 1-5.
10. Camilleri P., Haskins N. J., and Howlctt D. R. (1994) β-Cyclodextrin interacts with Alzheimer amyloid β-A4 peptide. FEBS Lett. 341, 256-258.
11. David-Salinas J. and Van Nostrand W. E. (1995) Amyloid β protein aggregation nullifies its pathologic properties in cultured cerebrovascular smooth muscle cells. J. Biol. Chem. 270, 20887-20890.
12. David-Salinas J., Saporito-Irwin S. M., Cotman C. W., and Van Nostrand W. E. (1995) Amyloid β-protein induces its own production in cultured degenerating cerebrovascular smooth muscle cells. J. Neurochem. 65, 931 -934.
13. Forloni G., Angeretti N., Chiesa R., Monzani E., Salmona M., Bugiani O., and Tagliavini F. (1993a) Neurotoxicity of a prion protein fragment. Nature 362, 543-545.
14. Forloni G., Chiesa R., Smiroldo S., Salmona M., Tagliavini F., and Angeretti N. (1993b) Apoptosis mediated neurotoxicity induced by chronic application of β amyloid fragment 25-35. Neuroreport 4, 523-526.
15. Forloni G., Bugiani O., Tagliavini F., and Salmona M. (1996) Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides. Prog. Neurobiol. 49, 287-315.
16. Games D., Adams D., Alessandrini R., Harbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523-527.
17. Goate A., Chartie-Harlin M. C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rossor M., Owen M., and Hardy J. (1991) Segregation of missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706.
18. Good T. A. and Murphy R. M. (1995) Aggregation state-dependent binding of β-amyloid peptide to protein and lipid components of rat cortical homogenates. Biochem. Biophys. Res. Commun. 207, 209-215.
19. Howlett D. R., Jennings K. H., Lee D. C., Clark M. S. G., Brown F., Wetzel R., Wood J. W., Camilleri P., and Roberts G. W. (1995) Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 4, 23-32.
20. LaFerla F. M., Tinkle B. T., Bierberich C. J., Haudenschild C. C., and Jay G. (1995) The Alzheimer's Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat. Genet. 9, 21-30.
21. Loo D. T., Copani A., Pike C. J., Whittemore E. R., Walencewicz A. J., and Cotman C. W. (1993) Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. USA 90, 7951-7955.
22. Ma J., Yee A., Brewer H. B., Das S., and Potter H. (1994) Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372, 92-94.
23. Mason R., Estermyr J., Kelly J., and Mason P. (1996) Alzheimer's disease amyloid β peptide 25-35 is localized in the membrane hydrocarbon core: x-ray diffraction analysis. Biochem. Biophys. Res. Commun. 222, 78-82.
24. Mattson M. P. and Rydel R. E. (1992) β-Amyloid precursor protein and Alzheimer's disease: the peptide plot thickens. Neurobiol. Aging 13, 617-621.
25. May P. C., Gitter B.D., Waters D. C., Simmons L. K., Becker G. W., Small J. S., and Robison P. M. (1992) β-Amyloid peptide in vitro toxicity: lot to lot variability. Neurobiol. Aging 13, 605-608.
26. Mazur-Kolecka B., Frackowiack J., and Wisniewski H. (1995) Apolipoprotein E3 and E4 induce, and transthyretin prevents, accumulation of the Alzheimer's β-amyloid peptide in cultured vascular smooth muscle cells. Brain Res. 698, 217-222.
27. 2+ concentration. Arch. Biochem. 269, 365-371.
28. Moechars D., Lorent K., De Strapper B., Dewachter I., and Leuven F. V. (1996) Expression in brain of amyloid precursor protein mutated in the α-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J. 15, 1265-1274.
29. Pike C. J., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1991) Aggregation-related toxicity of synthetic β-amyloid protein in hippocampal cultures. Eur. J. Pharmacol. 207, 367-368.
30. Pike C. J., Cummings B. J., and Cotman C. W. (1992) β-Amyloid induces neuritic dystrophy in vitro: similarities with Alzheimer pathology. Neuroreport 3, 369-372.
31. Pike C. J., Walencewicz-Wasserman A. J., Kosmoski J., Cribbs D. H., Glabe C. G., and Cotman C. W. (1995) Structure-activity analyses of β-amyloid peptides: contributions of the β25-35 region to aggregation and neurotoxicity. J. Neurochem. 64, 253-265.
32. Pollack S. J., Sadler I. I. J., Hawtin S. R., Tailor V. J., and Shearman , M. S. (1996) Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of β amyloid in rat PC 12 cells. Neurosci. Lett. 184, 113-116.
33. Roher A. E., Ball M. J., Bhave S. V., and Wakad A. R. (1991) β-Amyloid from Alzheimer's disease brain inhibits sprouting and survival of sympathetic neurons. Biochem. Biophys. Res. Commun. 174, 572-579.
34. Sadler I. I., Smith D. W., Shearman M. S., Ragan C. I., Tailor V. J., and Pollack S. J. (1996) Sulphated compounds attenuate β-amyloid toxicity by inhibiting its association with cells. Neuroreport 7, 49-53.
35. Selkoe D. (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498.
36. Tagliavini F., Giaccone G., Frangione B., and Bugiani O. (1988) Preamyioid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neurosci. Lett. 93, 191-196.
37. Terzi E., Hölzemann G., and Seelig J. (1994a) Reversible random coil-beta-sheet transition of the Alzheimer beta-amyloid fragment (25-35). Biochemistry 33, 1345-1350.
38. Terzi E., Hölzemann G., and Seelig J. (1994b) Alzheimer β-amyloid peptide 25-35: electrostatic interactions with phospholipid membranes. Biochemistry 33, 7434-7441.
39. Tomiyama T., Asano S., Suwa Y., Morita T., Kataoka K., Mon H., and Endo N. (1994) Rifampicin prevents the aggregation and neurotoxicity of amyloid β protein in vitro. Biochem. Biophys. Res. Commun. 204, 76-83.
40. Tomiyama T., Shoji A., Kataoka K., Suwa Y., Asano S., Kaneko H., and Endo N. (1996) Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin. J. Biol. Chem. 271, 6839-6844.
41. Woods A. G., Cribbs D. H., Whittemore E. R., and Cotman C. W. (1995) Heparin sulfate and chondroitin sulfate glycosaminoglycan attenuate β-amyloid (25-35) induced neurodegeneration in cultured hippocampal cells. Brain Res. 697, 53-62.
42. Yan S., Chen X., Fu J., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., and Schmidt A. (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691.
43. Yankner B. S., Duffy L. K., and Kirshner D. A. (1990) Neurotrophic and neurotoxic effects of β-amyloid protein: reversal by tachykinin neuropeptides. Science 250, 279-282.